Summary:
- Sangamo Therapeutics, a biotechnology company, is regaining full rights to its hemophilia A gene therapy program from its former collaborator Pfizer.
- The hemophilia A gene therapy is a potential treatment that aims to address the underlying genetic cause of the disease by delivering a functional copy of the F8 gene, which is responsible for producing the blood clotting factor VIII.
- This move allows Sangamo to independently develop and commercialize the hemophilia A gene therapy, potentially accelerating its progress towards clinical trials and regulatory approval.